Department of Neuroscience, School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. j.pawluski @ maastrichtuniversity.nl
Neuroendocrinology. 2012;95(1):39-46. doi: 10.1159/000329293. Epub 2011 Aug 31.
Selective serotonin reuptake inhibitor (SSRI) medications are the most common antidepressant treatment used during pregnancy and the postpartum period. Up to 10% of pregnant women are prescribed SSRIs. Serotonin plays an integral part in neurodevelopment, and questions have been raised about the placental transfer of SSRIs and the effects of preventing reuptake of presynaptic serotonin on fetal neurodevelopment. Preclinical data is beginning to document a role of early exposure to SSRIs in long-term developmental outcomes related to a number of brain regions, such as the hippocampus, cortex and cerebellum. To date, the majority of preclinical work has investigated the developmental effects of SSRIs in the offspring of healthy mothers; however, more research is needed on the effects of these medications in the face of maternal adversity. This minireview will highlight emerging evidence from clinical and preclinical studies investigating the impact of perinatal SSRI exposure on brain development and neural plasticity.
选择性 5-羟色胺再摄取抑制剂（SSRIs）是孕期和产后最常用的抗抑郁药物治疗方法。多达 10%的孕妇被开 SSRIs 药物。5-羟色胺在神经发育中起着重要作用，人们对 SSRIs 的胎盘转移以及防止突触前 5-羟色胺再摄取对胎儿神经发育的影响提出了质疑。临床前数据开始记录早期接触 SSRIs 与许多脑区（如海马体、大脑皮层和小脑）的长期发育结果之间的关系。迄今为止，大多数临床前工作都研究了 SSRIs 对健康母亲后代的发育影响；然而，在面对母亲逆境时，还需要更多的研究来了解这些药物的作用。这篇迷你综述将重点介绍来自临床和临床前研究的新证据，这些研究调查了围产期 SSRI 暴露对大脑发育和神经可塑性的影响。
